Gustavo A. Rosario Benitez

Array ( [id] => 11820632 [patent_doc_number] => 20170209569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'MONOVALENT ANTI-CD3 ADJUVANTS' [patent_app_type] => utility [patent_app_number] => 15/426745 [patent_app_country] => US [patent_app_date] => 2017-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 7649 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15426745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690906 [patent_doc_number] => 20170166622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/419398 [patent_app_country] => US [patent_app_date] => 2017-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 62541 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15419398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16016079 [patent_doc_number] => 20200182882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/072486 [patent_app_country] => US [patent_app_date] => 2017-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31331 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16072486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13278481 [patent_doc_number] => 10150812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-11 [patent_title] => CD3-binding molecules capable of binding to human and non-human CD3 [patent_app_type] => utility [patent_app_number] => 15/414303 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 36 [patent_no_of_words] => 34678 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729324 [patent_doc_number] => 20170190768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'COMPOSITIONS FOR SELECTIVE REDUCTION OF CIRCULATING BIOACTIVE SOLUBLE TNF AND METHODS FOR TREATING TNF-MEDIATED DISEASE' [patent_app_type] => utility [patent_app_number] => 15/408741 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10300 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15408741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851699 [patent_doc_number] => 20170226191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'INTRADERMAL ADMINISTRATION OF IMMUNOGLOBULIN G PREPARATION' [patent_app_type] => utility [patent_app_number] => 15/407139 [patent_app_country] => US [patent_app_date] => 2017-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 4567 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15407139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943292 [patent_doc_number] => 20170247443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'Safety and Efficacy with a CHO Cell Glycosylated Chimeric Antibody to TNF' [patent_app_type] => utility [patent_app_number] => 15/403115 [patent_app_country] => US [patent_app_date] => 2017-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 1557 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15403115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16229430 [patent_doc_number] => 10736960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => Methods for inhibiting fibrosis in a subject in need thereof [patent_app_type] => utility [patent_app_number] => 15/399524 [patent_app_country] => US [patent_app_date] => 2017-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 49 [patent_no_of_words] => 62954 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15399524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11588501 [patent_doc_number] => 20170112911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'Antigen-Specific T Cell Receptors and T Cell Epitopes' [patent_app_type] => utility [patent_app_number] => 15/392677 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 41149 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15392677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690945 [patent_doc_number] => 20170166660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation' [patent_app_type] => utility [patent_app_number] => 15/391396 [patent_app_country] => US [patent_app_date] => 2016-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 73 [patent_figures_cnt] => 73 [patent_no_of_words] => 98524 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15391396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706276 [patent_doc_number] => 20170174775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/386141 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 99 [patent_figures_cnt] => 99 [patent_no_of_words] => 55686 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706282 [patent_doc_number] => 20170174781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia' [patent_app_type] => utility [patent_app_number] => 15/386443 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 16203 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12043427 [patent_doc_number] => 09821011 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-11-21 [patent_title] => 'T-cell receptor-deficient T cell compositions' [patent_app_type] => utility [patent_app_number] => 15/383717 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14787 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15383717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12044747 [patent_doc_number] => 09822340 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-11-21 [patent_title] => 'T-cell receptor-deficient T cell compositions' [patent_app_type] => utility [patent_app_number] => 15/383662 [patent_app_country] => US [patent_app_date] => 2016-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14781 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15383662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866209 [patent_doc_number] => 20170233494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation' [patent_app_type] => utility [patent_app_number] => 15/376134 [patent_app_country] => US [patent_app_date] => 2016-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 79592 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15376134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690944 [patent_doc_number] => 20170166659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation' [patent_app_type] => utility [patent_app_number] => 15/372054 [patent_app_country] => US [patent_app_date] => 2016-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 98877 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15372054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13916715 [patent_doc_number] => 10202465 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-12 [patent_title] => Methods for treating conditions associated with MASP-2 dependent complement activation [patent_app_type] => utility [patent_app_number] => 15/371726 [patent_app_country] => US [patent_app_date] => 2016-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 63 [patent_no_of_words] => 74527 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15371726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11671557 [patent_doc_number] => 20170160278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'IgG Subtyping Assay for Identifying Transplantable Tissue Samples' [patent_app_type] => utility [patent_app_number] => 15/369097 [patent_app_country] => US [patent_app_date] => 2016-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 5515 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15369097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605984 [patent_doc_number] => 10906976 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Induction of immunotolerance to improve acceptance of tissue derived from pluripotent stem cells [patent_app_type] => utility [patent_app_number] => 15/360347 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 10 [patent_no_of_words] => 16455 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15360347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13574957 [patent_doc_number] => 20180339027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => PEPTIDES FROM NPSR1 [patent_app_type] => utility [patent_app_number] => 15/777880 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9705 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777880 [rel_patent_id] =>[rel_patent_doc_number] =>)